Answer
Levomepromazine maleate (Nozinan) and its non-hydroxylated metabolites are reported to potently inhibit CYP2D6, potentially increasing plasma concentrations of co-administered drugs primarily metabolised by this enzyme.
Sources for this answer
- Nozinan 25mg tabletsNeuraxpharm UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 21Document updated
Sources checked